"Then there is always the thought we could go it alone with the...

"Then there is always the thought we could go it alone with the support of our government and local biotech industry and create what could become a CSL 2.0. We don’t necessarily have to be bought out. "

If proven to work this would be a drug to be urgently produced and distributed around the world, a situation requiring quick assess to large production and distribution facilities already in existence and that Biotron does not have.

Incidentally, bellow is an extract from an article about big pharma modus operandi.

The pharma companies argue they have to bear the risk of developing experimental drugs that never make it to market. For example, the average cost of a new cancer drug has been estimated at $648 billion. The $2.6 billion figure cited from PHRMA above is actually a “risk weighted” estimate which “includes the cost of many failures”. If a pharma company invents 10 drugs costing $260 million each, but only one gets approved, then it has cost $2.6 billion overall to produce one it can sell.Except that isn’t what happens.

The reality is that major pharma companies only “invent” a handful of the drugs they patent and sell. In 2019, PHRMA’s member companies only spent $13 billion on preclinical research – most of their R&D spending goes on later stage development trials, after drugs have been discovered. An analysis of two Big Pharma giants shows that Pfizer only developed 10 out of 44 best-selling drugs “in house” (23%) – and Johnson & Johnson only developed 2 out of 18 (11%).

The “innovation” largely happens in university and government labs, or in those of smaller research companies. And a lot of it is state-funded. The US National Health Institutes, the main (but not the only) government medical research body, gives $39.2 billion a year to universities, medical schools and other research organisations.

Once the drugs have been found, the pharma giants step in – to buy up a license, or a whole company – once the drug has already proved itself through initial tests.